Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

  • News

Executive Summary

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

You may also be interested in...



Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed

The restructured Pfizer/Pharmacia sales force will begin operations in June

Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed

The restructured Pfizer/Pharmacia sales force will begin operations in June

Ortho-McNeil Adds Axert To Pain Portfolio; Pfizer Left With One Triptan

Ortho-McNeil will enter the triptan migraine class by taking over Pharmacia's marketing rights to Axert

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

See All
UsernamePublicRestriction

Register

PS041059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By